Search Results - "SABBATINI, R"

An update on the role of adipokines in arterial stiffness and hypertension by Sabbatini, Andréa R, Fontana, Vanessa, Laurent, Stephane, Moreno, Heitor

“…Adipokines are hormones produced by adipocytes and have been involved in multiple pathologic pathways, including inflammatory and cardiovascular complications…”
Get full text

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC by Knox, J.J., Barrios, C.H., Kim, T.M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S.Y., Flaig, T.W., Page, R.D., Beck, J.T., Cheung, F., Yadav, S., Patel, P., Geoffrois, L., Niolat, J., Berkowitz, N., Marker, M., Chen, D., Motzer, R.J.

“…RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the…”
Get full text

Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial by Lorusso, D., Ferrandina, G., Colombo, N., Pignata, S., Pietragalla, A., Sonetto, C., Pisano, C., Lapresa, M.T., Savarese, A., Tagliaferri, P., Lombardi, D., Cinieri, S., Breda, E., Sabatucci, I., Sabbatini, R., Conte, C., Cecere, S.C., Maltese, G., Scambia, G.

“…Increased Vascular Endothelial Growth Factor Receptor (VEGF) expression in endometrial cancer (EC) is associated with a poor prognosis. Preliminary clinical…”
Get full text

Subcellular Localization of Connexin 26 in Cardiomyocytes and in Cardiomyocyte-Derived Extracellular Vesicles by Falleni, Alessandra, Moscato, Stefania, Sabbatini, Antonietta R M, Bernardeschi, Margherita, Bianchi, Francesco, Cecchettini, Antonella, Mattii, Letizia

“…Connexins (Cxs) are a family of membrane-spanning proteins, expressed in vertebrates and named according to their molecular weight. They are involved in tissue…”
Get full text

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial by Lorusso, D., Scambia, G., Pignata, S., Sorio, R., Amadio, G., Lepori, S., Mosconi, A., Pisano, C., Mangili, G., Maltese, G., Sabbatini, R., Artioli, G., Gamucci, T., Di Napoli, M., Capoluongo, E., Ludovini, V., Raspagliesi, F., Ferrandina, G.

“…Current evidence suggest that trabectedin is particularly effective in cells lacking functional homologous recombination repair mechanisms. A prospective phase…”
Get full text

Resistant hypertension revisited: definition and true prevalence by Modolo, Rodrigo, de Faria, Ana P, Sabbatini, Andréa R, Moreno, Heitor

Get full text

The rs243866/243865 polymorphisms in MMP-2 gene and the relationship with BP control in obese resistant hypertensive subjects by Ritter, Alessandra M.V., de Faria, Ana Paula, Barbaro, Natália R., Sabbatini, Andréa R., Corrêa, Nathália Batista, Brunelli, Veridiana, Fattori, Andre, Amorim, Rivadavio, Modolo, Rodrigo, Moreno, Heitor

“…We sought to investigate whether the polymorphisms rs243865 (−1306C>T); rs243866 (−1575G>A) and rs2285053 (−735C>T) in metalloproteinases 2 - MMP-2 gene and…”
Get full text

Effects of leptin and leptin receptor SNPs on clinical- and metabolic-related traits in apparent treatment-resistant hypertension by de Faria, Ana Paula, Ritter, Alessandra M V, Sabbatini, Andréa R, Modolo, Rodrigo, Moreno, Heitor

“…Leptin is associated to the lack of blood pressure control as well as target organ damage in resistant hypertensive (RH) subjects. Single-nucleotide…”
Get full text

Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension by de Faria, Ana P C, Demacq, Caroline, Figueiredo, Valéria N, Moraes, Carolina H, Santos, Rodrigo C, Sabbatini, Andréa R, Barbaro, Natália R, Boer-Martins, Leandro, Fontana, Vanessa, Moreno, Jr, Heitor

“…Obesity, arterial stiffness and high aldosterone levels can interact to cause resistant hypertension (RHTN). Lower adiponectin (APN) levels may be…”
Get full text

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC by Knox, J J, Barrios, C H, Kim, T M, Cosgriff, T, Srimuninnimit, V, Pittman, K, Sabbatini, R, Rha, S Y, Flaig, T W, Page, R D, Beck, J T, Cheung, F, Yadav, S, Patel, P, Geoffrois, L, Niolat, J, Berkowitz, N, Marker, M, Chen, D, Motzer, R J

Get full text

Association of Mineralocorticoid Receptor Polymorphism I180V With Left Ventricular Hypertrophy in Resistant Hypertension by Ritter, Alessandra Mileni Versuti, Fontana, Vanessa, de Faria, Ana Paula Cabral, Modolo, Rodrigo, Barbaro, Natália R., Sabbatini, Andréa R., Peres, Heverton, Biagi, Celso, Silva, Pamela S., Lopes, Paulo C., Tanus-Santos, José Eduardo, Coelho, Eduardo B., Moreno, Heitor

“…OBJECTIVES Genetic polymorphisms on mineralocorticoid receptor gene (NC3C2) are associated with variability of mineralocorticoid receptor (MR) function and…”
Get full text

Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study by Vitale, M.G., Pipitone, S., Scagliarini, S., Zucali, P.A., Galli, L., Rossetti, S., Caserta, C., Iacovelli, R., Masini, C., Ficorella, C., Di Girolamo, S., Buti, S., Benedetti, B., Santoni, M., Porta, C., Bracarda, S., Baldessari, C., Giaquinta, S., Cascinu, S., Sabbatini, R.

Get full text

Modeling seed dormancy release and germination for predicting Avena fatua L. field emergence: A genetic algorithm approach by Blanco, Aníbal M., Chantre, Guillermo R., Lodovichi, Mariela V., Bandoni, J. Alberto, López, Ricardo L., Vigna, Mario R., Gigón, Ramón, Sabbatini, Mario R.

“…•Emergence was conceptualized as serial dormancy release and germination processes.•Dormancy release and germination were modeled as logistic…”
Get full text

Predictors of Silent Myocardial Ischemia in Resistant Hypertensive Patients by Modolo, Rodrigo, de Faria, Ana Paula, Paganelli, Maria O., Sabbatini, Andréa R., Barbaro, Natália R., Nascimento, Beatriz B., Ramos, Celso D., Fontana, Vanessa, Calhoun, David A., Moreno, Heitor

“…BACKGROUND Hypertension is the most prevalent and significant modifiable risk factor for coronary heart disease. A portion of patients with uncontrolled…”
Get full text

Adiponectin ‐11377C/G and +276G/T Polymorphisms affect Adiponectin Levels but do not Modify Responsiveness to Therapy in Resistant Hypertension by de Faria, Ana Paula C., Modolo, Rodrigo, Sabbatini, Andréa R., Barbaro, Natália R., Corrêa, Nathália B., Brunelli, Veridiana, Tanus‐Santos, José E., Fontana, Vanessa, Moreno, Heitor

“…Resistant hypertension (RHTN) is a multifactorial and polygenic disease, frequently associated with obesity. Low plasma adiponectin levels, a hormone produced…”
Get full text

2639 Effectiveness and possible Molecular factors predictive of clinical Outcomes in patients with transitional cell carcinoma of the urothelial tract (TCCU) treated with VInfluninE: A multicenter retrospective study (MOVIE) of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) by Passalacqua, R, Montironi, R, Lazzarelli, S, Donini, M, Perrucci, B, Nolè, F, Ceresoli, G.L, Pignata, S, Torricelli, F, Giannatempo, P, Doni, L, Ungari, M, Panni, S, Necchi, A, Betri, E, De Giorgi, U, Sabbatini, R, Rondini, E, Sequino, M, Caminiti, C

Get full text

Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension by Quinaglia, Thiago, de Faria, Ana Paula C., Fontana, Vanessa, Barbaro, Natália R., Sabbatini, Andréa R., Sertório, Jonas T., Demacq, Caroline, Tanus-Santos, José E., Moreno, Heitor

“…Purpose Failure to control blood pressure (BP) despite the use of three or more drugs characterizes resistant hypertension (RHTN). Impaired endothelial…”
Get full text

Does the number of nodes removed at the pelvic lymphadenectomy impact on cancer specific survival of pca patients with adverse pathological outcomes at radical prostatectomy? A retrospective 5- and 10-years analysis on 1274 series by Morini, E., Eissa, A., Sighinolfi, M.C., Bonfante, G., Vitale, M.G., Sandri, M., Sabbatini, R., Bruni, A., Romano, A., Peracchia, G., Grisanti, R., Reggiani Bonetti, L., Bagni, I., Micali, S., Rocco, B.

Get full text

5- and 10-years follow up of radical prostatectomy with pelvic lymphadenectomy: A cancer-specific survival analysis on a 1274 prostate cancer series by Bonfante, G., Sighinolfi, M.C., Morini, E., Sandri, M., Sabbatini, R., Vitale, M.G., Bruni, A., Romano, A., Peracchia, G., Grisanti, R., Reggiani Bonetti, L., Bgni, I., Micali, S., Bianchi, G., Rocco, B.

Get full text

Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting by Santini, Daniele, Virzi, Vladimir, Fratto, Maria Elisabetta, Bertoldo, Francesco, Sabbatini, Roberto, Berardi, Rossana, Calipari, Nicola, Ottaviani, Davide, Ibrahim, Toni

“…New emerging data suggest that bisphosphonates may exert antitumor properties. Preclinical studies have demonstrated that zoledronic acid (ZA) can induce…”
Get more information